• Sight Sciences

  Led · Series C · Oct 2017

  Sight Sciences closed an over $30M Series E Preferred Stock financing led by D1 Capital Partners. The company said it will use the funds for continued clinical and operational development and to support commercial expansion for its OMNI and TearCare products. Founded in 2011 by CEO Paul Badawi, Sight Sciences is based in Menlo Park, CA. Its OMNI Surgical System is a dually-indicated device that facilitates both trabeculotomy and transluminal viscoelastic delivery, allowing surgeons to target trabecular meshwork, Schlemm’s canal, and collector channels with a single corneal incision. TearCare is a software-controlled, wearable eyelid technology that delivers targeted, adjustable heat to the meibomian glands, leveraging SmartLid technology to facilitate natural meibum expression. Sight Sciences develops surgical and non-surgical medical devices to treat glaucoma and dry eye disease. Its surgical portfolio is led by the OMNI Surgical System, a multi-modal device that enables trabeculotomy and transluminal viscoelastic delivery to target all sources of resistance in the conventional outflow pathway. The non-surgical portfolio is anchored by TearCare, a software-controlled wearable eyelid system that delivers targeted, adjustable heat to the meibomian glands using SmartLid technology to facilitate natural meibum expression. The company plans to accelerate U.S. adoption of OMNI and TearCare, build a global commercial infrastructure in select international markets, and conduct additional clinical trials across its product portfolio. Sight Sciences also intends to develop a pipeline of innovations in new ophthalmic categories. Financially, it secured $56M in total 2019 financing—comprising a $31M Series D and a prior $25M debt facility—to fund these initiatives. Sight Sciences is a commercial-stage ophthalmic medical device company that develops technology-driven surgical and non-surgical solutions for ophthalmic diseases. The company operates two business lines: surgical devices (including TRAB®360 and VISCO360® and another surgical device in advanced development) and non-surgical technologies for dry eye disease. VISCO360® and TRAB®360 are commercially available in the United States, Europe and Canada; VISCO360® is available in the U.S. as a manual surgical tool and is investigational for IOP reduction in adult, pseudophakic patients with primary open angle glaucoma. Leadership includes President and CEO Paul Badawi and newly appointed Senior Vice President of Sales and Marketing Shawn O’Neil. Sight Sciences plans to use new funding to build out its U.S. commercial team, launch ophthalmic devices in Dry Eye and Microinvasive Surgery, scale manufacturing, and complete clinical studies to pursue expanded product indications and strategic product positioning. Sight Sciences is a commercial-stage ophthalmic medical device company based in Menlo Park, CA, led by President and CEO Paul Badawi. It operates both surgical and non-surgical device business lines. The surgical portfolio includes the TRAB™360 and VISCO™360 devices. The non-surgical portfolio comprises technologies in advanced stages of development for evaporative dry eye. The company closed a $7M Series B financing to support growth. It intends to use the proceeds to build out the management team, scale manufacturing, support product development, and initiate a series of clinical studies.

No current team members are available.